MYGNMyriad Genetics, Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -94% · now 49% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can MYGN take a bad year?
The deepest fall in MYGN's price history on file is −94%; it is 49% below its high today.
Net debt · as at Q2 2027 · debt less the cash on hand, with no positive EBITDA to service it
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 80%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −94%
Worst drawdown on file · −49% today
Details›
- Total debtQ2 2027
- $121M
- Cash and short-term investments
- $115M
- Net debt
- $5.5M
- EBITDA, trailing twelve months
- −$64M
- Operating profit, trailing twelve months
- −$99M
- Debt / equity
- 0.40×
- Annualised volatilitytwo years of daily moves
- 80%
- Worst drawdown on file
- −94%
- Below its 52-week high
- 49%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Diagnostics & Research
Ranks #17 of 21 by RyuScore